Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ The cost of Gilead’s HIV prevention pill has counteracted widespread use, the study shows

The cost of Gilead’s HIV prevention pill has counteracted widespread use, the study shows



Tthe escalating price of the only HIV prevention pill may have been a key factor preventing widespread use in recent years, according to a new analysis by U.S. government researchers, which underscores long-standing concerns about the ability to eradicate the virus.

From 2014 to 2018, total payments made by public programs, commercial insurance companies and patients for Truvada, which was approved to prevent HIV in 2012, jumped from $ 114 million to nearly $ 2.1 billion. Still, the number of people who received a prescription in 2018 was only 204,700, which was less than 20% of those estimated to have benefited from the medication.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days for free!

GET STARTED




Source link